{"questions":[{"id":"open_question-269af2f1-696a-4b61-aecf-824b5a1574fe","artifact_type":"open_question","title":"How can Epidemiology signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:46.716149+00:00","updated_at":"2026-04-26T03:29:46.716149+00:00"},{"id":"open_question-db850ec9-5aeb-4af0-89b5-ef317452e948","artifact_type":"open_question","title":"How can Pain, Clinical research signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:38.169674+00:00","updated_at":"2026-04-26T03:27:38.169674+00:00"},{"id":"open_question-38d8ff7a-a645-4ab9-ab21-78c8ceb6346b","artifact_type":"open_question","title":"How can Amyloid, APP processing signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:36.914710+00:00","updated_at":"2026-04-26T03:28:36.914710+00:00"},{"id":"open_question-90996af6-0869-48fc-8122-d8ff9de9feba","artifact_type":"open_question","title":"How can Vascular cognitive impairment signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:36.970336+00:00","updated_at":"2026-04-26T03:28:36.970336+00:00"},{"id":"open_question-cae3f33d-c521-41eb-a129-de88719231be","artifact_type":"open_question","title":"How can Biomarkers, Amyloid, Prevention signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:44.208527+00:00","updated_at":"2026-04-26T03:29:44.208527+00:00"},{"id":"open_question-819f992d-4971-496f-bbbd-124c8684e555","artifact_type":"open_question","title":"How can Single-Cell Genomics, Spatial Transcriptomics, Cell Types signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:47.821223+00:00","updated_at":"2026-04-26T03:29:47.821223+00:00"},{"id":"open_question-46fe4d77-2fcd-422e-9a61-7b7531e8204c","artifact_type":"open_question","title":"How can Clinical trials, Care research signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:37.022840+00:00","updated_at":"2026-04-26T03:29:37.022840+00:00"},{"id":"open_question-ca5050ef-f2cd-4968-bbf5-50c7fd974397","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Cognitive decline into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:36.914694+00:00","updated_at":"2026-04-26T03:29:36.914694+00:00"},{"id":"open_question-226982ca-c66f-4ac0-b279-4f7a4edbdd73","artifact_type":"open_question","title":"How can Risk factors, Prevention, Sleep signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:36.857617+00:00","updated_at":"2026-04-26T03:29:36.857617+00:00"},{"id":"open_question-282550ae-fc58-4729-8c1d-45b72c153918","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Neuropsychiatric Disorders and Alzheimer Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:29.731056+00:00","updated_at":"2026-04-26T03:29:29.731056+00:00"},{"id":"open_question-785a6f7d-7295-43d6-816a-c72e9228b610","artifact_type":"open_question","title":"How can Prevention, Biomarkers signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:18.789965+00:00","updated_at":"2026-04-26T03:29:18.789965+00:00"},{"id":"open_question-1c31c230-fe91-4108-b222-975fcb96b1ff","artifact_type":"open_question","title":"How can Funding, Research programs signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:18.529811+00:00","updated_at":"2026-04-26T03:29:18.529811+00:00"},{"id":"open_question-f529ef72-0481-41e6-a91d-189ca5c75ac4","artifact_type":"open_question","title":"How can Gamma-secretase, APP processing, Drug discovery signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:33.729706+00:00","updated_at":"2026-04-26T03:29:33.729706+00:00"},{"id":"open_question-642754e6-5f66-4f8a-a2c6-efaa408bca05","artifact_type":"open_question","title":"How can Clinical trials, Biomarkers signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:33.138848+00:00","updated_at":"2026-04-26T03:29:33.138848+00:00"},{"id":"open_question-e6053212-8778-41da-8e75-7c6c3b830e2f","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Parkinson's Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:45.234627+00:00","updated_at":"2026-04-26T03:29:45.234627+00:00"},{"id":"open_question-b5c44514-dc37-4102-ac01-bb685ee7f01c","artifact_type":"open_question","title":"Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:47.881291+00:00","updated_at":"2026-04-26T03:25:47.881291+00:00"},{"id":"open_question-1cce1a08-8b69-4240-a24c-0cb2b2a0fd8e","artifact_type":"open_question","title":"How can Genetics, Epidemiology signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:31.003505+00:00","updated_at":"2026-04-26T03:27:31.003505+00:00"},{"id":"open_question-bb6b3e04-5fea-4555-9f0c-2581dd7779cf","artifact_type":"open_question","title":"How can Cholinergic, Neurotrophic factors signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:42.979271+00:00","updated_at":"2026-04-26T03:28:42.979271+00:00"},{"id":"open_question-eea99adc-ceb4-4828-a042-1b21d791a777","artifact_type":"open_question","title":"How can Epigenetics, Histone deacetylases, Memory signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:36.556290+00:00","updated_at":"2026-04-26T03:26:36.556290+00:00"},{"id":"open_question-1e7219dd-18fa-48c5-a553-f68779330551","artifact_type":"open_question","title":"How can Sleep, Memory consolidation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:36.626400+00:00","updated_at":"2026-04-26T03:26:36.626400+00:00"},{"id":"open_question-25d2b891-e0aa-4219-84a2-ab6f4232f842","artifact_type":"open_question","title":"How can Prions, Protein Misfolding, Amyloid, Neurodegeneration signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:15.064492+00:00","updated_at":"2026-04-26T03:29:15.064492+00:00"},{"id":"open_question-db6684c5-8014-47da-a283-741f3b8e8b9f","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Prion Disease and Alzheimer Disease and Parkinson Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:15.119375+00:00","updated_at":"2026-04-26T03:29:15.119375+00:00"},{"id":"open_question-2258f76a-06e7-4288-a6da-ce9d39c09167","artifact_type":"open_question","title":"How can Cell Types, Transcriptomics, Connectomics, Brain Development signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:19.080093+00:00","updated_at":"2026-04-26T03:28:19.080093+00:00"},{"id":"open_question-21129684-7794-42fd-a524-97dfd90b6adc","artifact_type":"open_question","title":"How can Genetics signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:33.701334+00:00","updated_at":"2026-04-26T03:27:33.701334+00:00"},{"id":"open_question-dabf88ae-40ec-42cb-be0a-8f4b47e85934","artifact_type":"open_question","title":"How can Vesicle Trafficking, Autophagy, Endoplasmic Reticulum signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:38.463787+00:00","updated_at":"2026-04-26T03:26:38.463787+00:00"},{"id":"open_question-25e344ec-cf8b-4deb-b9e1-43e5a96a5c94","artifact_type":"open_question","title":"How can Bioinformatics, Systems biology signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:19.590155+00:00","updated_at":"2026-04-26T03:28:19.590155+00:00"},{"id":"open_question-c523726b-2bc0-4d53-9e5d-cc4d9f0870c8","artifact_type":"open_question","title":"How can Biomarkers, Neurofilament, Tau, Alpha-synuclein signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:15.929337+00:00","updated_at":"2026-04-26T03:29:15.929337+00:00"},{"id":"open_question-7163ae0b-9bc9-4246-9244-e5a52f3a670a","artifact_type":"open_question","title":"How can Tau, Neuroimaging signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:57.658960+00:00","updated_at":"2026-04-26T03:26:57.658960+00:00"},{"id":"open_question-342c9193-622a-46c9-8162-ad8e504d69a6","artifact_type":"open_question","title":"How can Neuroinflammation, Microglia signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:35.926786+00:00","updated_at":"2026-04-26T03:27:35.926786+00:00"},{"id":"open_question-e90f0e57-629b-43bd-b965-f50935961608","artifact_type":"open_question","title":"How can Clinical research signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:36.307736+00:00","updated_at":"2026-04-26T03:27:36.307736+00:00"},{"id":"open_question-d1de89b0-8440-4b5e-878a-0eb76828b42b","artifact_type":"open_question","title":"How can Clinical trials, Acetylcholinesterase signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:20.607717+00:00","updated_at":"2026-04-26T03:28:20.607717+00:00"},{"id":"open_question-952c6536-f9d2-4482-bccd-f77663393149","artifact_type":"open_question","title":"How can Amyloid, Neural circuits signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:21.103692+00:00","updated_at":"2026-04-26T03:28:21.103692+00:00"},{"id":"open_question-a5616c4a-9f8e-412c-b561-12c18b32b5ea","artifact_type":"open_question","title":"How can Clinical trials signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:47.636478+00:00","updated_at":"2026-04-26T03:25:47.636478+00:00"},{"id":"open_question-4aea949c-4ca6-4590-bbd4-8e9e5104382a","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:48.083900+00:00","updated_at":"2026-04-26T03:25:48.083900+00:00"},{"id":"open_question-ec053a83-4103-472c-a3ba-7c0e78097e55","artifact_type":"open_question","title":"How can Functional Neuroimaging, Default Mode Network, Brain Metabolism signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:56.777683+00:00","updated_at":"2026-04-26T03:28:56.777683+00:00"},{"id":"open_question-68e9570f-8f94-4e18-a675-b038cb4d02cf","artifact_type":"open_question","title":"How can Biomarkers, Clinical trials signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:01.175615+00:00","updated_at":"2026-04-26T03:27:01.175615+00:00"},{"id":"open_question-e76da80c-6a19-4cd2-adce-49bef6e441f5","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:56.836317+00:00","updated_at":"2026-04-26T03:28:56.836317+00:00"},{"id":"open_question-8e029bd3-c791-4ebf-b256-d1621d3c3f0c","artifact_type":"open_question","title":"How can Apoptosis, Calorie restriction, Mitochondrial dysfunction signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:01.458833+00:00","updated_at":"2026-04-26T03:27:01.458833+00:00"},{"id":"open_question-12ce1f72-c78d-4a8a-a6c2-8d966171a0a7","artifact_type":"open_question","title":"How can Genetics, Ubiquitin-proteasome system signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:39.723830+00:00","updated_at":"2026-04-26T03:27:39.723830+00:00"},{"id":"open_question-6709910a-ae0b-4c5e-848a-6db2c8b1e515","artifact_type":"open_question","title":"How can LDL Receptor, Cholesterol Metabolism, Statins signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:52.259623+00:00","updated_at":"2026-04-26T03:27:52.259623+00:00"},{"id":"open_question-153bf644-c7d1-408f-a556-ff53a26062e9","artifact_type":"open_question","title":"How can Biomarkers, CSF, Tau, Amyloid signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:24.016923+00:00","updated_at":"2026-04-26T03:28:24.016923+00:00"},{"id":"open_question-2aacdb37-73f5-44cd-b0fd-9a5588872c91","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Cardiovascular Disease and Familial Hypercholesterolemia into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:52.319403+00:00","updated_at":"2026-04-26T03:27:52.319403+00:00"},{"id":"open_question-009fbe2c-9d46-4357-9e6e-5c4eb87dfd92","artifact_type":"open_question","title":"How can Genetics, APP, Risk genes signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:24.067736+00:00","updated_at":"2026-04-26T03:28:24.067736+00:00"},{"id":"open_question-c7c670c4-32d7-4cf9-825e-154e31c05728","artifact_type":"open_question","title":"How can Prions, Neuroinflammation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:25.304609+00:00","updated_at":"2026-04-26T03:28:25.304609+00:00"},{"id":"open_question-16f5b21a-ed41-4788-8bef-13c5a9beeb35","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Prion diseases and Alzheimer's Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:25.374645+00:00","updated_at":"2026-04-26T03:28:25.374645+00:00"},{"id":"open_question-4fb0f7d3-8aeb-4a60-ad3c-760b57abb5b0","artifact_type":"open_question","title":"How can Tau, RNA, Genetics signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:58.557758+00:00","updated_at":"2026-04-26T03:28:58.557758+00:00"},{"id":"open_question-94e14a0e-d9b4-4a1c-98c9-9666571021dc","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Huntington's Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:58.609548+00:00","updated_at":"2026-04-26T03:28:58.609548+00:00"},{"id":"open_question-d46fa111-6e4f-415f-92c4-1169acf444bd","artifact_type":"open_question","title":"How can Amyloid, Genetics, APP processing signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:55.719592+00:00","updated_at":"2026-04-26T03:25:55.719592+00:00"},{"id":"open_question-619938f8-1855-4b37-9a8d-d0954627aae4","artifact_type":"open_question","title":"How can Clinical care, Research funding signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:54.477703+00:00","updated_at":"2026-04-26T03:27:54.477703+00:00"},{"id":"open_question-02ac901f-7f26-45a1-b09b-07f069a5e320","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Parkinson's Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:55.830312+00:00","updated_at":"2026-04-26T03:25:55.830312+00:00"},{"id":"open_question-bc1a8deb-3490-4756-8211-acc98fcf38b1","artifact_type":"open_question","title":"How can TDP-43, Clinical pathology signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:54.534866+00:00","updated_at":"2026-04-26T03:27:54.534866+00:00"},{"id":"open_question-09bbd8ed-c32b-4324-a8c1-46e0fc5a807f","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and FTD into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:54.594766+00:00","updated_at":"2026-04-26T03:27:54.594766+00:00"},{"id":"open_question-73298e8b-ea8c-4404-b6e1-8e3941d75918","artifact_type":"open_question","title":"How can Purinergic signaling, Astrocytes signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:59.328815+00:00","updated_at":"2026-04-26T03:28:59.328815+00:00"},{"id":"open_question-956473af-8da0-4b9d-b457-6ec83e41cae8","artifact_type":"open_question","title":"How can Vascular, APOE signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:56.459097+00:00","updated_at":"2026-04-26T03:25:56.459097+00:00"},{"id":"open_question-6ef14d1e-f9f2-44ce-b1b9-5219644d8a87","artifact_type":"open_question","title":"How can Gamma-secretase, APP Processing, Amyloid signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:59.790608+00:00","updated_at":"2026-04-26T03:28:59.790608+00:00"},{"id":"open_question-e903ae2f-9f41-4f51-93de-091066c6644e","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Frontotemporal Dementia into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:59.852579+00:00","updated_at":"2026-04-26T03:28:59.852579+00:00"},{"id":"open_question-7a5d8ae1-1630-43fe-88b6-e9a59cb57608","artifact_type":"open_question","title":"How can Memory Formation, Synaptic Plasticity, Hippocampus signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:05.426206+00:00","updated_at":"2026-04-26T03:27:05.426206+00:00"},{"id":"open_question-5355438f-8142-4696-9502-04ebb945376f","artifact_type":"open_question","title":"How can Synaptic Transmission, SNARE Complex, Synaptotagmin signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:29.654479+00:00","updated_at":"2026-04-26T03:29:29.654479+00:00"},{"id":"open_question-06926e24-2782-49cd-be42-cebc30c8bd84","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer Disease and Memory Disorders into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:05.500631+00:00","updated_at":"2026-04-26T03:27:05.500631+00:00"},{"id":"open_question-83156cb4-01d5-4daa-a02b-ff2d4ad43653","artifact_type":"open_question","title":"How can Neuroinformatics signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:00.662270+00:00","updated_at":"2026-04-26T03:29:00.662270+00:00"},{"id":"open_question-5ed09eec-5b80-4c6e-b807-f58d6616f38e","artifact_type":"open_question","title":"How can Frailty, Clinical outcomes signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:00.792621+00:00","updated_at":"2026-04-26T03:29:00.792621+00:00"},{"id":"open_question-f4ed333d-7eb1-427b-bcb0-f991c4b1d061","artifact_type":"open_question","title":"How can APP, BACE1, Cell biology signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.289656+00:00","updated_at":"2026-04-26T03:27:56.289656+00:00"},{"id":"open_question-f67f6f82-3a8a-4ecb-86b5-5066fb9bd989","artifact_type":"open_question","title":"How can Neuroimaging, Biomarkers signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:06.088751+00:00","updated_at":"2026-04-26T03:27:06.088751+00:00"},{"id":"open_question-979fdf01-4ecf-4f77-99a6-33352f0f6126","artifact_type":"open_question","title":"How can Genetics, Amyloid, Neuroinflammation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:58.417038+00:00","updated_at":"2026-04-26T03:25:58.417038+00:00"},{"id":"open_question-934820d7-ac64-4dff-899d-a21fa7c269b1","artifact_type":"open_question","title":"How can Biomarkers, Diagnostics signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.100491+00:00","updated_at":"2026-04-26T03:27:57.100491+00:00"},{"id":"open_question-2cb21c06-0706-4587-8045-b88483f42b62","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Lewy Body into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.163397+00:00","updated_at":"2026-04-26T03:27:57.163397+00:00"},{"id":"open_question-99a8c7b6-2789-4192-a513-8aee788f2025","artifact_type":"open_question","title":"How can Stem cells, Regenerative medicine signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:24.075793+00:00","updated_at":"2026-04-26T03:26:24.075793+00:00"},{"id":"open_question-7dfa0d77-ddb0-4765-959a-341c0ca72617","artifact_type":"open_question","title":"How can [Tau](/proteins/tau), Neuroinflammation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:25.533901+00:00","updated_at":"2026-04-26T03:26:25.533901+00:00"},{"id":"open_question-1a9f3eb3-8d48-47ec-b09d-d32c7dfc972b","artifact_type":"open_question","title":"How can Neuroinflammation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:25.608006+00:00","updated_at":"2026-04-26T03:26:25.608006+00:00"},{"id":"open_question-c1c87dbf-e8e5-4738-9630-7adc860780f9","artifact_type":"open_question","title":"How can Oxidative stress signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:25.691772+00:00","updated_at":"2026-04-26T03:26:25.691772+00:00"},{"id":"open_question-2763d788-5bea-447a-82f9-00a4641e8bc1","artifact_type":"open_question","title":"How can Vesicle Fusion, SNARE Proteins, Exocytosis signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:25.887755+00:00","updated_at":"2026-04-26T03:26:25.887755+00:00"},{"id":"open_question-905a3e8d-9f98-4d42-9e48-a7f58f987c33","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Neurodegenerative Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:25.997811+00:00","updated_at":"2026-04-26T03:26:25.997811+00:00"},{"id":"open_question-1122ecae-5783-4efd-8aa5-9a9ccf20f37b","artifact_type":"open_question","title":"How can Amyloid, APOE, Sleep signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:09.145310+00:00","updated_at":"2026-04-26T03:27:09.145310+00:00"},{"id":"open_question-2999096c-598d-4374-928c-81fb02312a04","artifact_type":"open_question","title":"How can Neural stem cells signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:58.742096+00:00","updated_at":"2026-04-26T03:27:58.742096+00:00"},{"id":"open_question-1d7a0ff2-03b3-4bd0-96a8-f125a788cec6","artifact_type":"open_question","title":"How can Biomarkers, Prion protein signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:58.815399+00:00","updated_at":"2026-04-26T03:27:58.815399+00:00"},{"id":"open_question-13787531-c264-4e61-b598-01dc36c09398","artifact_type":"open_question","title":"How can Clinical trials, Immunotherapy signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:03.088468+00:00","updated_at":"2026-04-26T03:29:03.088468+00:00"},{"id":"open_question-f07f7fda-5513-4fd6-a0a4-7670c0c858b2","artifact_type":"open_question","title":"How can LDL Receptor, Cholesterol Metabolism signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:48.517724+00:00","updated_at":"2026-04-26T03:29:48.517724+00:00"},{"id":"open_question-5cd6aff0-8659-404e-ad16-ecf4a574f37a","artifact_type":"open_question","title":"How can Transcriptomics, Cell Types, Developmental Neurobiology, Epigenomics signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:27.971745+00:00","updated_at":"2026-04-26T03:26:27.971745+00:00"},{"id":"open_question-10b2aad4-2a4a-4716-a0b4-7ef3649ecf64","artifact_type":"open_question","title":"How can Synaptic plasticity, Prefrontal cortex signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:39.020867+00:00","updated_at":"2026-04-26T03:28:39.020867+00:00"},{"id":"open_question-77803e3b-e7a7-4caf-b6b5-3f0d9d2227e3","artifact_type":"open_question","title":"How can Cell Replacement Therapy, Neural Transplantation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:25.821976+00:00","updated_at":"2026-04-26T03:27:25.821976+00:00"},{"id":"open_question-e63e9f27-e027-4038-b3e0-44cb2ba36009","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Parkinson's Disease and Huntington's Disease into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:25.882175+00:00","updated_at":"2026-04-26T03:27:25.882175+00:00"},{"id":"open_question-5d7ebade-4a6c-408e-9968-cbc28a849e44","artifact_type":"open_question","title":"How can Genetics, Drug development signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:29.459010+00:00","updated_at":"2026-04-26T03:26:29.459010+00:00"},{"id":"open_question-8786efd0-7764-459c-a5e9-979b35938663","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Psychiatric disorders into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:29.519893+00:00","updated_at":"2026-04-26T03:26:29.519893+00:00"},{"id":"open_question-7c3c337f-85b5-4b44-a595-1dc0d24dcde8","artifact_type":"open_question","title":"How can Historical signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:26.094166+00:00","updated_at":"2026-04-26T03:27:26.094166+00:00"},{"id":"open_question-2db1b8f6-7ca3-4bfb-b93d-3673351c6d7b","artifact_type":"open_question","title":"How can Amyloid signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:26.156445+00:00","updated_at":"2026-04-26T03:27:26.156445+00:00"},{"id":"open_question-0253446b-d6fd-45fa-96a8-8258bb1bd02b","artifact_type":"open_question","title":"How can Neuroimaging signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:26.210660+00:00","updated_at":"2026-04-26T03:27:26.210660+00:00"},{"id":"open_question-9ea9d3c6-ac59-4545-9c9c-f27ce668e9bc","artifact_type":"open_question","title":"How can Alpha-synuclein, TDP-43, Protein aggregation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:26.265956+00:00","updated_at":"2026-04-26T03:27:26.265956+00:00"},{"id":"open_question-15fce6b0-2ce2-4247-b11a-27e08a99caaa","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Parkinson's Disease and ALS into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:26.325737+00:00","updated_at":"2026-04-26T03:27:26.325737+00:00"},{"id":"open_question-a598ff1c-821b-42e2-9f68-ed55c4a48ee8","artifact_type":"open_question","title":"How can Biomarkers signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:30.379326+00:00","updated_at":"2026-04-26T03:26:30.379326+00:00"},{"id":"open_question-00dce3b6-6f18-4925-b647-03d5dde8b717","artifact_type":"open_question","title":"How can Biomarkers, Mathematical modeling signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:40.505992+00:00","updated_at":"2026-04-26T03:28:40.505992+00:00"},{"id":"open_question-da8a7b4e-87d2-42db-9921-c14ba4d69483","artifact_type":"open_question","title":"How can Mitochondrial dysfunction signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:12.465267+00:00","updated_at":"2026-04-26T03:29:12.465267+00:00"},{"id":"open_question-0584444d-4ea6-4693-9ec1-19309fb48556","artifact_type":"open_question","title":"How can [Genomics](/entities/genomics), [Network medicine](/entities/network-medicine), [Systems biology](/entities/systems-biology) signals be standardized across cohorts and sites without losing dis","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:26.856311+00:00","updated_at":"2026-04-26T03:27:26.856311+00:00"},{"id":"open_question-7c809a4d-683a-4987-8f79-42b7c928bce5","artifact_type":"open_question","title":"How can Protein aggregation signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:14.637359+00:00","updated_at":"2026-04-26T03:28:14.637359+00:00"},{"id":"open_question-7d4a572c-fe71-4d11-93a4-a271cbdb9c74","artifact_type":"open_question","title":"How can Neuropharmacology signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:14.735109+00:00","updated_at":"2026-04-26T03:28:14.735109+00:00"},{"id":"open_question-6f9610ae-4500-48d5-a861-f27961209d50","artifact_type":"open_question","title":"How can Amyloid, APP Processing, Alpha-secretase signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:27.672605+00:00","updated_at":"2026-04-26T03:27:27.672605+00:00"},{"id":"open_question-02c3647b-a381-4320-999b-bade1bb4c79c","artifact_type":"open_question","title":"What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Down Syndrome into clinically meaningful interventions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:27.851207+00:00","updated_at":"2026-04-26T03:27:27.851207+00:00"},{"id":"open_question-8c2effa3-1677-46a6-9630-99362e42f2b5","artifact_type":"open_question","title":"How can Machine Learning, Genomic Data Integration, Spatial Transcriptomics, Single-Cell Analysis signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:42.128949+00:00","updated_at":"2026-04-26T03:28:42.128949+00:00"},{"id":"open_question-researchers-thy-duy-d58344a3","artifact_type":"open_question","title":"Therapeutic monitoring","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-researchers-anthony-lang-483bc302","artifact_type":"open_question","title":"Precision Medicine","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-researchers-anthony-lang-e0100d60","artifact_type":"open_question","title":"Early Diagnosis","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"}],"total":113,"limit":100,"offset":0,"returned":100,"sort":"importance_elo","field":"researchers"}